We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Questions about the source of clinical trial data submitted by Dr. Reddy’s have caused the FDA to take another look at the company’s new drug application (NDA) for a generic version of Pfizer’s hypertension and angina drug Norvasc.
Pfizer won’t have to face a legal battle involving the death of a child who killed himself after six days of taking the company’s antidepressant Zoloft (sertraline HCI), after a federal appeals court refused to reinstate a wrongful death lawsuit brought by the parents.
Citing the potential far-reaching impact of the decision, the FDA said last week that it will appeal a court ruling overturning the agency’s decision to grant shared 180-day exclusivity to several generic firms seeking to market a version of GlaxoSmithKline’s depression drug Paxil (paroxetine HCl).
Wyeth’s appeal to the U.S. Supreme Court of a 10-year-old lawsuit revolving around the reformulation of a prenatal supplement could set a legal precedent for patent law in the United States, if the court agrees to hear the case.
A 10-year-old lawsuit against Wyeth being considered for possible review by the U.S. Supreme Court could set a legal precedent for patent law in the United States.
An AIDS advocacy group has filed a lawsuit against Abbott Laboratories, alleging the company is manipulating markets and violating antitrust laws with its decision to increase the price of its HIV drug Norvir (ritonavir) nearly fivefold.
A federal appeals court has refused to reinstate a wrongful death lawsuit against Pfizer brought by the parents of a child who killed himself after six days of taking the company’s antidepressant Zoloft (sertraline HCl).
GlaxoSmithKline (GSK) has filed a lawsuit in Israel seeking a court order to stop generic drugmaker Dexxon from marketing a version of GSK's indigestion drug Zantac (ranitidine HCl) under the similar trademark Zanidex.
A U.S. district judge was wrong to bar Mylan Laboratories from continuing to sell the cancer drug paclitaxel pending an appeal of an earlier ruling that those sales infringed on NaPro Biotherapeutics’ formulation patents, a federal appeals court has ruled.